Highland Capital Management (Tennessee)’s AbbVie ABBV Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11M	Sell	43,576 -824	-2%	-$177K	0.5%	41
2026 Q1	$9.66M	Sell	44,400 -6,096	-12%	-$1.35M	0.51%	43
2025 Q4	$11.5M	Buy	50,496 +9,365	+23%	+$2.13M	0.57%	35
2025 Q3	$9.52M	Sell	41,131 -5,703	-12%	-$1.16M	0.47%	47
2025 Q2	$8.69M	Sell	46,834 -19	-0%	-$3.53K	0.47%	49
2025 Q1	$9.82M	Buy	46,853 +2,792	+6%	+$543K	0.59%	39
2024 Q4	$7.83M	Sell	44,061 -2,670	-6%	-$491K	0.45%	55
2024 Q3	$9.23M	Buy	46,731 +23,563	+102%	+$4.4M	0.53%	45
2024 Q2	$3.97M	Sell	23,168 -3,291	-12%	-$545K	0.23%	109
2024 Q1	$4.82M	Sell	26,459 -46	-0.2%	-$7.93K	0.28%	98
2023 Q4	$4.11M	Sell	26,505 -53	-0.2%	-$7.73K	0.26%	111
2023 Q3	$3.96M	Sell	26,558 -7,549	-22%	-$1.11M	0.27%	107
2023 Q2	$4.6M	Sell	34,107 -3,989	-10%	-$585K	0.3%	108
2023 Q1	$6.07M	Buy	38,096 +11,038	+41%	+$1.69M	0.45%	59
2022 Q4	$4.37M	Sell	27,058 -775	-3%	-$119K	0.31%	99
2022 Q3	$3.73M	Buy	27,833 +392	+1%	+$56.3K	0.29%	106
2022 Q2	$4.2M	Buy	27,441 +250	+0.9%	+$38.2K	0.3%	105
2022 Q1	$4.41M	Sell	27,191 -159	-0.6%	-$23.1K	0.26%	121
2021 Q4	$3.7M	Sell	27,350 -298	-1%	-$35.2K	0.21%	129
2021 Q3	$2.98M	Sell	27,648 -46,669	-63%	-$5.33M	0.18%	147
2021 Q2	$8.37M	Sell	74,317 -3,206	-4%	-$361K	0.5%	54
2021 Q1	$8.39M	Buy	77,523 +46,443	+149%	+$4.97M	0.52%	55
2020 Q4	$3.33M	Sell	31,080 -2,680	-8%	-$258K	0.21%	126
2020 Q3	$2.96M	Sell	33,760 -6	-0%	-$565	0.21%	125
2020 Q2	$3.31M	Buy	33,766 +8,030	+31%	+$707K	0.26%	108
2020 Q1	$1.96M	Sell	25,736 -4,199	-14%	-$358K	0.18%	126
2019 Q4	$2.65M	Buy	+29,935	New	+$2.49M	0.18%	132
2019 Q3	–	Sell	-21,738	Closed	-$1.58M	–	307
2019 Q2	$1.58M	Sell	21,738 -294	-1%	-$23.1K	0.12%	182
2019 Q1	$1.78M	Sell	22,032 -1,289	-6%	-$105K	0.13%	162
2018 Q4	$2.15M	Sell	23,321 -29	-0.1%	-$2.55K	0.18%	131
2018 Q3	$2.21M	Buy	23,350 +1,557	+7%	+$148K	0.16%	144
2018 Q2	$2.02M	Sell	21,793 -1,700	-7%	-$166K	0.15%	149
2018 Q1	$2.22M	Buy	23,493 +2,701	+13%	+$297K	0.17%	139
2017 Q4	$2.01M	Sell	20,792 -4,187	-17%	-$395K	0.15%	144
2017 Q3	$2.22M	Buy	24,979 +9,769	+64%	+$744K	0.18%	137
2017 Q2	$1.1M	Sell	15,210 -21,259	-58%	-$1.43M	0.09%	179
2017 Q1	$2.38M	Buy	36,469 +2,891	+9%	+$182K	0.2%	128
2016 Q4	$2.1M	Buy	33,578 +174	+0.5%	+$10.6K	0.18%	136
2016 Q3	$2.11M	Sell	33,404 -1,760	-5%	-$114K	0.18%	141
2016 Q2	$2.18M	Buy	35,164 +3,831	+12%	+$233K	0.19%	136
2016 Q1	$1.79M	Buy	+31,333	New	+$1.75M	0.15%	148
2015 Q4	–	Sell	-2,410	Closed	-$131K	–	310
2015 Q3	$131K	Sell	2,410 -1,930	-44%	-$126K	0.01%	318
2015 Q2	$292K	Buy	+4,340	New	+$283K	0.02%	297

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Highland Capital Management (Tennessee)'s ABBV Position: Q2 2026 in Review

Highland Capital Management (Tennessee) reduced its AbbVie (ABBV) stake by 1.9% in Q2 2026, selling an estimated $177K and leaving 43,576 shares worth $11M. The position accounts for 0.5% of the portfolio, ranked #41.

Highland Capital Management (Tennessee) first reported a position in ABBV in Q2 2015 and has held it in 43 quarters since. The position peaked at $11.5M in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Highland Capital Management (Tennessee) held 43,576 shares of AbbVie worth $11M as of Q2 2026.
Highland Capital Management (Tennessee) sold 824 AbbVie shares in Q2 2026, an estimated $177K.
AbbVie made up 0.5% of Highland Capital Management (Tennessee)'s portfolio in Q2 2026, its #41 holding.
Highland Capital Management (Tennessee) first reported a position in AbbVie in Q2 2015 and has held it in 43 quarters since.
Highland Capital Management (Tennessee)'s AbbVie position peaked at $11.5M in Q4 2025.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.